
Brand Name | Status | Last Update |
|---|---|---|
| clinisol | ANDA | 2018-06-01 |
| kabiven | New Drug Application | 2023-08-02 |
| perikabiven | New Drug Application | 2023-08-07 |
| plenamine | ANDA | 2023-04-21 |
| premasol - sulfite-free (amino acid) | ANDA | 2022-08-04 |
| prosol | New Drug Application | 2020-10-07 |
| trophamine | New Drug Application | 2023-11-27 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | D-glutamate |
| INN | — |
| Description | D-glutamic acid is an optically active form of glutamic acid having D-configuration. It has a role as an Escherichia coli metabolite and a mouse metabolite. It is a D-alpha-amino acid and a glutamic acid. It is a conjugate acid of a D-glutamate(1-). It is an enantiomer of a L-glutamic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | N[C@H](CCC(=O)O)C(=O)O |
| PDB | — |
| CAS-ID | 6893-26-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL76232 |
| ChEBI ID | 15966 |
| PubChem CID | 23327 |
| DrugBank | DB02517 |
| UNII ID | — |
